Featured Press Releases

Novotech receives new investment from GIC, Temasek, and existing investor TPG to accelerate global growth

Novotech receives new investment from GIC, Temasek, and existing investor TPG to accelerate global growth

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

  • 30 Apr 2025

Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free...

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Bruker has acquired Dynamic Biosensors, a pioneer in single-cell interaction cytometry systems, aimed at enhancing drug discovery efforts

Bruker has acquired Dynamic Biosensors, a pioneer in single-cell interaction cytometry systems, aimed at enhancing drug discovery efforts

HanAll Biopharma releases Q3 2024 financial results and shares business updates

HanAll Biopharma releases Q3 2024 financial results and shares business updates

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

  • Tonix Pharmaceuticals Holding Corp.
  • 30 Jan 2026
China approves Libevitug, first-in-class therapy for hepatitis D

China approves Libevitug, first-in-class therapy for hepatitis D

  • Huahui Health Ltd.
  • 28 Jan 2026
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

  • Johnson & Johnson
  • 27 Jan 2026
Correction — Privo Technologies

Correction — Privo Technologies

  • Privo Technologies
  • 26 Jan 2026
HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

  • HanchorBio Inc.
  • 26 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.